Divi's Laboratories Limited (NSE:DIVISLAB)

Market Cap	1.83T +12.4%
Revenue (ttm)	105.60B +12.8%
Net Income	25.68B +17.2%
EPS	96.75 +17.2%
Shares Out	265.47M
PE Ratio	71.18
Forward PE	59.63
Dividend	30.00 (0.44%)
Ex-Dividend Date	Jul 25, 2025

Volume	354,155
Average Volume	334,397
Open	6,858.00
Previous Close	6,858.00
Day's Range	6,790.00 - 6,960.50
52-Week Range	5,636.50 - 7,071.50
Beta	0.22
RSI	66.48
Earnings Date	May 23, 2026

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its pro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 10,542
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DIVISLAB

Financial Performance

In fiscal year 2026, Divi's Laboratories's revenue was 105.60 billion, an increase of 12.82% compared to the previous year's 93.60 billion. Earnings were 25.68 billion, an increase of 17.21%.